New Subcutaneous DMPA Access Collaborative Launched

DateOctober 30, 2017
SourcePATH
TypeVideos and Webinars

Access to a range of contraceptive choices allows each woman to find an option that works best for her. The all-in-one injectable contraceptive, subcutaneous DMPA* (DMPA-SC, marketed as Pfizer’s Sayana® Press**) can overcome access barriers by enabling health worker administration in new and remote locations, and even self-injection.

Between 2017 and 2020, the Subcutaneous DMPA Access Collaborative led by PATH and John Snow, Inc. (JSI) will work with ministries of health and partners in 8 to 12 countries to facilitate DMPA-SC introduction and scale-up planning, and provide technical assistance to ensure implementation of each country's total market plan.

The recording and slides from this webinar are now available online. 

Learnmore button
Tags
Injectables Long-acting and permanent methods PATH Scale-up